At BPI (BioProcess International Europe) our Supply Chain Director, María Dolores Gálvez, presented:
“Use of enzymatic DNA for the Production of AAV for Gene Therapy”.
Now, you can watch the video of this session where Gálvez presented TAAV and neDNA™:
neDNA™ is TAAV-manufactured enzymatic DNA. This innovative technology presents an alternative to plasmid DNA for the manufacture of recombinant adeno-associated virus (rAAV). Our disruptive technology is creating a new industry standard for transfection-based rAAV production.
Would you like to know more about neDNA™? Download our brochure and explore about this innovative enzymatic DNA for rAVV manufacturing.